Orphan Drugs & Rare Diseases 2013 is a conference that covers topics such as:
- How research & development and market access costs must be controlled
- Unique `Big Pharma Spotlight` sessions to understand current pipelines
- Case studies of new molecules in clinical trials
- Optimal targeting of a new drug by reviewing it with patient groups to engage rare diseases
- Current funding options; including financial and economic reimbursement for the clinical development of drugs
Orphan Drugs & Rare Diseases 2013 brings together attendees from pharma and biotech companies, CROs, regulatory bodies and legal experts involved in:
- Legislation and Policy Advice
- Intellectual Property
- Licensing
- Business Development
- APIs
- Manufacturing
- Drug and Safety Assessment
- Bioequivalence
- Regulatory Affairs
- Market Strategy
